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Abstract
Background: Mutations in the transcription factor SOX18 are responsible for specific cardiovascular defects in humans and
mice. In order to gain insight into the molecular basis of its action, we identified target genes of SOX18 and analyzed one,
MMP7, in detail.
Methodology/Principal Findings: SOX18 was expressed in HUVEC using a recombinant adenoviral vector and the altered
gene expression profile was analyzed using microarrays. Expression of several regulated candidate SOX18 target genes was
verified by real-time PCR. Knock-down of SOX18 using RNA interference was then used to confirm the effect of the
transcription factor on selected genes that included the guidance molecules ephrin B2 and semaphorin 3G. One gene,
MMP7, was chosen for further analysis, including detailed promoter studies using reporter gene assays, electrophoretic
mobility shift analysis and chromatin-immunoprecipitation, revealing that it responds directly to SOX18. Immunohisto-
chemical analysis demonstrated the co-expression of SOX18 and MMP7 in blood vessels of human skin.
Conclusions/Significance: The identification of MMP7 as a direct SOX18 target gene as well as other potential candidates
including guidance molecules provides a molecular basis for the proposed function of this transcription factor in the
regulation of vessel formation.
Citation: Hoeth M, Niederleithner H, Hofer-Warbinek R, Bilban M, Mayer H, et al. (2012) The Transcription Factor SOX18 Regulates the Expression of Matrix
Metalloproteinase 7 and Guidance Molecules in Human Endothelial Cells. PLoS ONE 7(1): e30982. doi:10.1371/journal.pone.0030982
Editor: Pieter H. Reitsma, Leiden University Medical Center, Netherlands
Received March 29, 2011; Accepted December 29, 2011; Published January 23, 2012
Copyright:  2012 Hoeth et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work was supported by grants from the Austrian Science Foundation (FWF; www.fwf.ac.at) within the Austrian Angiogenesis Network (NFN S9405)
to RdM, and P20940-B11 (to PP). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: rainer.demartin@meduniwien.ac.at
¤a Current address: Baxter Innovations GmbH, Vienna, Austria
¤b Current address: Austrian Science Fund, Vienna, Austria
Introduction
The SOX family of High Mobility Group (HMG) box
transcription factors plays important roles in embryonic devel-
opment. SOX18, together with SOX7 and SOX17, constitutes
the subgroup F within this family. Mutations in SOX18 are the
underlying cause of hypotrichosis-lymphedema-telangiectasia
(HLT) in humans, a disease that is characterized by sparse hair,
bleeding and lymphedema [1]. A similar phenotype (ragged)e x i s t s
in mice and is characterized not only by the name-giving coat
defects but also by cardiovascular abnormalities, e.g., edema,
cyanosis, dilation, distention and rupture of peripheral blood
vessels, including lymphatic defects [2–5]. The structure of
SOX18 comprises an N-terminal DNA binding domain, a
central transactivation domain, and a C-terminal region that
contains a recently discovered additional transactivation motif
[6]. Several of the cognate mutations in murine Sox18 are
located in a short region at the end of the central transactivation
and the beginning of the C-terminal part, leading to premature
stop codons, and thereby generating dominant-negative (dn)
proteins. In contrast to the ragged alleles, Sox18
2/2 mice show
only a mild phenotype [7] which, though it may in part be
explained by strain differences, suggests that other transcription
factors, possibly members of the Sox subgroup F family, may
have redundant function [8]. Indeed, the generation of Sox18/
Sox17 double mutant mice has at least partially supported this
view [9,10].
In the developing mouse embryo, Sox18 is expressed in the
allantois and yolk sack blood islands, in the heart, the paired dorsal
aortae, in expanding intersomitic and peripheral vessels, in the
pancreas, and in nascent vibrissae follicles [5,11]. In chickens,
expression has been described in feather follicles [12], and in
humans in fetal brain [13]. In Xenopus laevis, sox18 together with
sox7 appears to be necessary for cardiogenesis [14]. The combined
knock-down of SOX18 and SOX7 in the zebrafish resulted in
defective arteriovenous specification [15,16].
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and the inter-ventricular septum of the heart [17]. In the
vasculature, it is transiently expressed in capillaries within
granulation tissue of skin wounds [18]. In atherosclerotic lesions,
SOX18 was localized to endothelial cells of the vasa vasorum and
intimal neovessels, and also to vascular smooth muscle cells (SMC)
in the intima [19]. Expression was also detected in human
umbilical vein endothelial cells (HUVEC) and SMC in culture,
and found to be necessary for SMC growth in an in vitro injury
model [19].
Together, the phenotypes observed in human as well as in
different experimental model organisms suggest a predominant
role of SOX18 in the vasculature, both during development and in
the adult. The finding of its expression in a number of tumor cell
lines [19], the observation that ragged mice show reduced growth of
vascularized tumors [20], and the successful inhibition of tumor
angiogenesis using cell-permeable dn SOX18 mutants [21]
support the view that SOX18 could be a valuable target for
interfering with (tumor) angiogenesis. However, despite these
important aspects, very little is known about the molecular
mechanisms underlying the function(s) of SOX18, i.e. which genes
are regulated by the transcription factor. The most prominent one
in the context of lymphatic vasculature development is Prox1,
however, it requires the venous endothelial-specific nuclear
hormone receptor Coup-TFII [2,22] Two other target genes,
VCAM-1 and the m-opioid receptor, have been described
previously [23,24], however, these can only partially explain the
observed phenotypes. Another one, Claudin-5, was reported more
recently [25]. Since claudins constitute tight junction strands and
maintain cellular barriers, impaired expression could account for
the observed edema formation in individuals affected by SOX18
mutations. However, claudin-5 knock-out mice did not show a
corresponding phenotype [26]. Last not least, ROBO4 was found
to be transcriptionally regulated by Sox18 in the zebrafish,
suggesting a role for Sox18 in vessel guidance [27].
We present here the results of a more global approach aiming at
the identification of SOX18 target genes in endothelial cells. Using
ectopic SOX18 expression in primary human endothelial cells
followed by microarray-based gene expression analysis, we have
obtained a comprehensive list of potential target genes. Selected
genes were confirmed by real-time PCR and by knock-down
experiments. In addition, and to verify the validity of the
approach, we have characterized the SOX18-dependent regula-
tion of one of them in more detail, namely matrix metalloprotei-
nase (MMP7). The multiple biological effects of this protein during




Human SOX7, SOX17, and SOX18 cDNAs were isolated by
RT-PCR from HUVEC and cloned into the vector pCMV-myc
(Clontech). Promoter fragments for MMP7 (345 and 196 bps) were
isolated by PCR (High Fidelity, Roche), and inserted into the
luciferase reporter vector pUBT-Luc [28]. Mutation of the
potential SOX18 binding site in the MMP7 promoter was done
using the QuikChange Mutagenesis Kit (Stratagene). The
sequence of the primers used for construction is given in Table
S1. All constructs were verified by sequencing.
Cell culture and transfection
HEK293 cells were obtained from ATCC. HUVEC were
isolated from human umbilical cords derived from human
subjects and propagated as described previously [29]. The use of
human umbilical cords for the isolation of HUVEC and the use
of skin samples has been approved by the Ethics Commission of
the Medical University of Vienna. Written informed consent was
obtained from all patients (in the case of umbilical cords, written
informed consent was obtained from the parents). Umbilical
cords and skin samples were obtained from the Department of
Obstetrics and Gynecology, and the Department of Dermatol-
ogy, respectively, both at the Vienna General Hospital, Medical
University of Vienna. HEK293 cells were transfected with the
different reporter constructs using the calcium-phosphate
method. All transfections were done in triplicates. Luciferase
levels were normalized for ß-Gal expression.
RNA interference
HUVEC were grown in 6-well plates and transfected with
siRNAs using polyethylenimine (PEI). The final concentrations in
the transfection mix were 250 mM siRNAs and 0.003% PEI.
siRNAs directed against either human SOX18, SOX17 or control
were purchased from Ambion. Primer sequences are given in
Table S1.
Recombinant adenoviral vectors
SOX18 was inserted into pIRES-EGFP (Clontech), and then the
entire SOX18-IRES-EGFP casette was subcloned into the
adenoviral transfer vector pACCMVpLpASR+ [30]. The control
vector contained only the IRES-EGFP part. Recombinant
adenovirus (Adv) was generated by recombination in HEK293
cells as described previously [29]. For transduction, HUVEC were
washed twice with serum-free medium and incubated with the
adenovirus at a final conc. of 10
8 pfu/ml for 30 min., followed by
replacement with complete medium.
Microarray analysis
RNA was isolated from non-transduced, Adv-SOX18 and
control Adv transduced HUVEC using the RNeasy Mini Kit
(Qiagen). Probe labeling and hybridization to HG-U133A 2.0
arrays (Affymetrix) interrogating the expression of 18.400
transcripts, as well as data analysis, was done as described
previously [31]. Data conforming to MIAME standards were
deposited in the GEO database under the accession nr.
GSE8952.
Real-time PCR
Expression of selected genes was analyzed using a LightCycler
with Fast Start SYBR Green I Kit (Roche). Values were
normalized for ß2 microglobulin expression. Primers were
designed using the program Primer3. Results were confirmed by
different sources of RNA. Primer sequences are given in Table S1.
Electrophoretic mobility shift assay
The Lightshift chemiluminescence EMSA Kit (Pierce) was used
with biotinylated oligonucleotides as given in the supplemental
materials. Competition experiments were carried out using a 100-
fold excess of unlabelled oligonucleotides with either the same, a
mutated, or an unrelated sequence. Primer sequences are given in
Table S1.
Chromatin Immunoprecipitation
We used a protocol with two-step cross-linking as decribed [32].
Briefly, 10
7 cells were pelleted and incubated with 2 mM
disuccinylglutarate in PBS for 45 min at room temp, washed with
PBS, and crosslinked with 1% paraformaldehyde for 15 min. at
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cells were washed and suspended in cold lysis buffer containing
protease inhibitors (Roche). After 10 min on ice, DNA was
sonicated 46 for 25 sec. at 25% power (Branson Sonic Power
Company B-12 sonifyer). Debris was removed by centrifugation
and the samples stored at 270uC. After pre-clearing with protein
A sepharose, 100 ml aliquots were incubated with 2 mg of different
anti-SOX18 antibodies (Santa Cruz sc-20100, Thermo Scientific
Table 1. Top SOX18 regulated genes.
Accession-nr Gene symbol Name Induction (Sox/EGFP)
Up-regulated
NM_003925 MBD4 methyl-CpG binding domain protein 4 36.90
NM_014421 DKK2 dickkopf (Xenopus laevis) homolog 2 22.10*
NM_002674 PMCH pro-melanin-concentrating hormone 20.83{
NM_013230 CD24 CD24 14.64
NM_004440 EPHA7 ephrin receptor A7 11.41*
NM_001321 CSRP2 cysteine and glycine-rich protein 2 8.41
NM_002185 IL7R interleukin 7 receptor 5.82*
NM_015148 PASK PAS domain S/T kinase 4.72
NM_012069 ATP1B4 ATPase, (Na+)K+ transporting, beta 4 4.65
NM_004392 DACH dachshund (Drosophila) homolog 4.63
NM_003467 CXCR4 chemokine receptor 4 4.57*
NM_018455 FLJ13607 bone marrow protein BM039 4.56
NM_000909 NPYR neuropeptide Y receptor 4.52*
NM_016593 CYP39A1 oxysterol 7alpha-hydroxylase 4.40
NM_020469 ABO histo-blood group ABO protein 4.26
NM_001870 CPA3 carboxypeptidase A3 4.13
NM_004093 EFNB2 ephrinB2 3.81*
NM_015068 PEG10 Paternally expressed 10 3.69
NM_016315 GULP1 engulfment adaptor PTB domain 1 3.51
NM_004783 TAO1 thousand and one amino acid protein kinase 3.39
NM_002423 MMP7 matrix metalloproteinase 7 3.38*
NM_006339 HMG20B high-mobility group 20B 3.38
NM_018676 TMTSP thrombospondin module 3.36
NM_000104 CYP1B1 cytochrome P450, subfamily I 3.33
NM_006558 KHDRBS3 Sam68-like phosphotyrosine protein 3.26
NM_005093 CBFA2T2 core-binding factor, alpha subunit 2 3.19
NM_005127 CLEC2B C-type lectin domain family 2B 3.16
NM_016083 CNR1 CB1 cannabinoid receptor 3.14*
NM_021624 HRH4 histamine H4 receptor 3.14
NM_002245 KCNK1 potassium channel, subfamily K, member 1 3.05
NM_020163 SEMA3G Semaphorin3G 2.40*
Down-regulated
NM_005681 TAF1A TATA box binding protein-associated factor 0.10
NM_017850 FLJ20508 0.15
NM_005011 NRF1 nuclear respiratory factor 1 0.15
NM_005461 KRML maf-related leucine zipper homolog 0.15
AL049226 DKFZp564M0916 0.17
XM_937246 FLJ13765 BANP homolog 0.22
NM_018903 PCDH-alpha12 VE-cadherin 2 long isoform 0.23{
NM_001191 BCL2L1 Bcl-xS 0.23
NM_000156 GATM guanidinoacetate N-methyltransferase 0.25
*verified by real-time PCR;
{induction by real-time PCR was 1.5-fold;
{no change in real-time PCR.
doi:10.1371/journal.pone.0030982.t001
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precipitated with blocked protein A sepharose, and washed with
buffer containing increasing salt concentrations. The antibody was
eluted from the DNA-protein complex in 1% SDS/0.1 M sodium
bicarbonate, the agarose removed by centrifugation, and cross-
linking reversed by addition of NaCl to a final conc. of 0.2 M and
incubation at 65uC for 4 hours. DNA was purified over Qiagen
columns, and analyzed by PCR using the primers given in Table
S1. The anti-Sox18 antibody recognized Sox17 10–20 times less
efficiently, no detectable cross-reactivity with Sox7 was observed
(Figure S2).
Immunohistochemistry
Serial sections from paraffin-embedded normal human trunk
skin were stained with rabbit antibodies against SOX18 (sc-20100;
1:2500, Santa Cruz), MMP7 (ab4044, Abcam, 1:500), LYVE-1
(102PA50, Research Diagnostics, Inc., 1:100), or von Willebrand
factor (A0082, Dako, 1:5000), followed by incubation with
biotinylated secondary antibody (BA-1000, anti rabbit IgG, Vector
Laboratories, 1:200). Bound antibodies were visualized by
incubation with a streptavidin-HRP conjugate (Dako) and 3-
amino-9-ethylcarbazole resulting in a red reaction product.
Sections were counterstained with haematoxylin.
Results
Identification of SOX18 target genes
Our strategy to identify SOX18 target genes was to ectopically
express the transcription factor in primary endothelial cells
followed by microarray analysis of the resulting gene repertoire.
In order to achieve high transfection efficiency we generated a
SOX18 adenoviral vector containing an IRES-EGFP cassette.
The control virus contained the IRES-EGFP cassette alone. As
judged by EGFP expression, transduction efficiency was close to
100%. As assayed by real-time PCR, expression of Sox18 was
approx. 70-fold higher as compared to controls (Figure S1), and
did not alter Sox7 and -17 levels. Expression of selected candidate
genes was confirmed by real-time PCR. Knock-down of SOX18 by
RNA interference was then used as a complementary approach to
verify the dependence of selected genes on the transcription factor.
In order to obtain primary target genes and avoid the isolation
of genes that are up-regulated secondary to the induction of others,
we harvested the SOX18 expressing HUVEC at an early time
point after transduction. SOX18 protein could be detected as early
as 16 hours (not shown). RNA from SOX18-, EGFP-, and non-
transduced HUVEC was subjected to microarray analysis. Using a
threshold of 3-fold changes, 30 genes were found to be
Figure 1. Real-time PCR analysis of SOX18 target genes. RNA was isolated from non-transduced (mock), control virus (AdvEGFP) and SOX18
adenovirus (AdvSOX18) transduced HUVEC and analyzed for the expression of matrix metalloproteinase 7 (MMP7), ephrinB2 (EFNB2), EPHA7,
semaphorin 3G (SEMA3G), interleukin 7 receptor (IL-7R), and cannabinoid receptor 1 (CNR1). Values were normalized for ß2 microglobulin expression,
and are expressed as fold induction compared to control cells.
doi:10.1371/journal.pone.0030982.g001
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transcripts, Table 1). Selected genes were further analyzed using
real-time PCR, and induction was confirmed for MMP7, ephrin-
B2 (EFNB2), EPHA7, semaphorin 3G (SEMA3G), interleukin 7
receptor (IL-7R), cannabinoid receptor 1 (CNR1) (Figure 1), and
others (Table 1). Whereas the published expression of VCAM-1
Figure 2. Knock-down of SOX18 diminishes the expression of target genes. HUVEC were transfected with siRNAs directed against SOX17 or
SOX18, or with a scrambled control (Scr), and expression of target genes analyzed by real-time PCR. Values were normalized for ß2 microglobulin
levels, and are expressed as fold induction compared to control cells.
doi:10.1371/journal.pone.0030982.g002
Figure 3. Promoter analysis of MMP7. A, Schematic representation of the two MMP7 promoter-luciferase reporter constructs containing either
only the proximal or both potential SOX18 binding sites (black diamonds). B, the wild type (wt) constructs were cotransfected together with
increasing amounts of SOX18, SOX7 or SOX17 expression vectors into HEK293 cells as indicated. Luciferase values were normalized for ß-Gal
expression. C, in the shorter construct, the single potential SOX18 binding site was mutated. D, The short MMP7 promoter construct containing the
mutated SOX18 binding site was analyzed as in (B).
doi:10.1371/journal.pone.0030982.g003
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were found to be 2-fold increased in the array (not shown). The
entire data set has been deposited in the GEO data base (NCBI)
under the accession nr. GSE8952.
In a complementary approach we then knocked down SOX18
in HUVEC (and also SOX17 which has been reported to have
partially redundant function) using siRNA, and analyzed a subset
of genes by real-time PCR. Of these transcripts, MMP7, EFNB2,
and SEMA3G were reduced by SOX18 knock-down (Figure 2), the
last two also responded to SOX17 knock-down. Two genes (CNR1
and EPHA7) responded weakly, whereas IL-7R expression was
enhanced (data not shown).
MMP7 is a direct target gene of SOX18
Based on its multiple functions in angiogenesis [33–37] and
clear response to SOX18 in the overexpression and knock-down
experiments, we selected MMP7 for further analysis. A set of
experiments was performed to investigate whether it is a primary
target or expressed indirectly, i.e., secondary to other regulators
that may have been induced by SOX18. A direct target gene is
supposed to contain one or more functional SOX18 binding site(s)
in the promoter. We therefore analyzed the MMP7 promoter by
reporter gene analysis including mutation of the potential SOX18
binding site, binding of SOX18 in vitro using electrophoretic
mobility shift assay (EMSA), and in vivo using chromatin
immunoprecipitation (ChIP).
First, bioinformatic analysis using the program TOUCAN [38]
revealed the presence of two potential SOX18 binding sites. We
isolated two promoter fragments that contained either both or only
the proximal site (Figure 3A), and cloned them into the luciferase
reporter vector UBT-Luc [28]. Cotransfection of these constructs
together with SOX18 resulted in a strong dose-dependent
induction of both MMP7 promoter constructs. In contrast,
cotransfected SOX7 or SOX17, the other members of the
subgroup F, had only negligible effects (Figure 3B). Since
cotransfection experiments showed that the proximal SOX18
binding site is sufficient to induce a strong response only this site
was chosen for mutation experiments. Its mutation (Figure 3C)
resulted in strongly diminished MMP7 induction, demonstrating
that this site is functional (Figure 3D). Some activity was observed
with high amounts of co-transfected Sox18, possibly reflecting
non-physiological effects. Furthermore, the short MMP7 promoter
construct did not respond to cotransfected SOX7 or SOX17, the
latter being in line with the lack of response to knock-down of
SOX17 (Figure 3D).
Next, we determined whether SOX18 binds to the proximal site
in vitro and in vivo. EMSA revealed that nuclear extracts from
HUVEC contained a protein binding to the SOX18 binding site,
and competition experiments using unlabelled wild type (wt) and
mutated oligonucleotides demonstrated the specificity of binding
(Figure 4A). However, probably due to technical reasons we were
not able to perform a conclusive supershift to directly demonstrate
the presence of Sox18 in the complex. HUVEC also express Sox-7
and -17, so in order to assess whether this site was indeed occupied
by SOX18 in vivo, we performed ChIP. Using primers flanking the
proximal SOX18 binding site in the MMP7 promoter, a specific
band could be detected by PCR after precipitation with three
different SOX18 antibodies, but not with a control antibody
(Figure 4B). Since the Sox18 antibody from SantaCruz recognizes
a region with some homology to the other SoxF group members
we tested its specificity and found a weak cross-reactivity (1/10–1/
20) with Sox17, and none with Sox7 (Figure S2). The Sox18
antibody from Chemicon recognizes an N-terminal 17 aa peptide
sequence specific for Sox18. The correct identity of the amplified
bands was confirmed by sequencing. Therefore, and in accor-
dance with the reporter and EMSA data, binding of SOX18 to the
proximal MMP7 SOX18 binding site could be demonstrated. We
conclude that, using the criteria of in vitro and in vivo binding and of
reporter gene analysis, MMP7 contains at least one functional
SOX18 binding site and represents a direct SOX18 target gene.
Figure 4. SOX18 binds to the proximal site in the MMP7
promoter in vitro and in vivo. A, Electrophoretic mobility shift assay
(EMSA). Binding of SOX18 to its proximal site in the MMP7 promoter
was analyzed using nuclear extracts from HUVEC. Specificity of binding
was demonstrated by competition experiments using the same (wt), a
mutated (mut) or an unrelated (unrel) oligonucleotide as indicated, the
specific complex is indicated by an arrow. B, The same site was analyzed
by chromatin immunoprecipitation in HUVEC. Lane 1–3: different a-
Sox18 antibodies (SantaCruz, Thermo, Chemicon, respectively) as
described in Materials and Methods, Ig: IgG control antibody; inp:
input, M: 100 bp marker. The 120 bp PCR fragments obtained after
amplification ofDNA precipitated by the anti-SOX18 antibodies and
input DNA are marked by an arrow.
doi:10.1371/journal.pone.0030982.g004
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SOX18 has previously been found to be expressed in endothelial
and smooth muscle cells [19]. To correlate SOX18 expression with
its target gene we performed immunohistochemical analysis of
serial sections of normal adult human skin samples (Figure 5). We
found SOX18 expressed in arteries, veins and some small
capillaries, the latter all being LYVE1 negative and thus belonging
to the blood vessel tree. SOX18 positive vessels co-expressed
MMP7. Moreover, SOX18 stained positive in the muscularis of
arteries and veins, and these also expressed MMP7. The lack of a
complete correlation of SOX18 and MMP7 expression might be
due to the fact that MMP7 is also expressed in other cells and in
response to stimuli that do not utilize SOX18 (e.g., FGF regulates
MMP7 via AP1) [39], or due to diffusion of MMP7 as a secreted
protein. Sections were stained with von Willebrand factor to
identify all vessels, and LYVE1 for lymphatics. Of note, all
lymphatics were negative for SOX18. Furthermore, we have
analyzed tissue arrays containing 300 skin samples from basal cell
carcinomas of a total of 100 different patients. Similar to the
situation in normal skin, all LYVE1 positive lymphatics were
negative for SOX18 (data not shown). Although these findings are
in contrast with the notion that mutations in SOX18 affect the
lymphatic vasculature [2], it may well be that these alterations
occur during development and persist during adulthood without
the necessity for continued expression of SOX18.
Discussion
The notion that SOX18 plays an important role in angiogenesis
is well supported by the occurrence of mutations in humans and
mice that result in vascular (including lymphatic) defects; however,
mechanistic insight how this transcription factor exerts its function
is still very limited. As a first step to answer this question we have
identified SOX18 target genes; one of them, MMP7, was analyzed
in more detail, and we could show that it represents a direct
SOX18 target gene. A recent study described lower levels of
Mmp7 and Il-7r in ragged mice [40]; while the former is supported
by our findings, our data were controversial about the latter:
Although expression of IL-7R was upregulated upon SOX18
overexpression, it was not reduced, for reasons unknown, upon
knock-down in our experimental system.
In vascular cells, multiple functions have been described for
MMP7. In general, MMPs degrade a broad variety of proteins,
including extracellular matrix proteins. MMP7 substrates include
proteoglycans, fibronectin, elastin and casein. SOX18 dependent
expression of MMP7 during angiogenesis could therefore function
to promote the sprouting process. However, MMP7 appears to
have more functions than just clearing barriers: It has been
implicated in ectodomain shedding of several cell surface
molecules, including heparin-binding epidermal growth factor
precursor, membrane-bound Fas ligand, E-cadherin, and TNFa
precursor, all of which are cleaved to release the respective soluble
forms [35]. Moreover, VEGF-165, which is bound by connective
tissue growth factor, can be released from this inactive complex by
MMP7 [34]. Similarly, KC, a member of the CXC family of small
chemokines can be liberated from its complex with syndecan-1,
thereby generating a KC gradient capable of directing neutrophil
migration [33]. These biological activities would suggest a pro-
angiogenic function.
However, also anti-angiogenic properties have been attributed
to MMP7. First, it can cleave plasminogen and collagen XVIII to
generate angiostatin, as well as a 28 kD endostatin-spanning
fragment, respectively [41]. Moreover, it cleaves decorin, a
proteoglycan that can serve as a reservoir for TGF-ß, a potent
anti-angiogenic factor in the extracellular matrix [36]. In a mouse
model of corneal wound healing, MMP7 served as an inhibitor of
corneal avascularity [37]. Therefore, the net outcome of SOX18
dependent MMP7 expression cannot be predicted, and may
depend on the specific site and context of the angiogenic process.
Beside MMP7, we have identified several other potential target
genes of SOX18. Combining SOX18 overexpression with the
more stringent criterion of SOX18 knock-down, EFNB2 and
Figure 5. SOX18 and MMP7 are co-expressed in arteries and veins, but not in lymphatic vessels. Serial sections from human skin were
analyzed by immunohistochemical staining with the indicated antibodies. Endothelial cells were revealed by von Willebrand factor (vWF) staining,
lymphatic vessels by LYVE-1.
doi:10.1371/journal.pone.0030982.g005
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that MMP7 responded only to SOX18 knock-down, whereas the
other two were dependent (however, to a lesser degree) on SOX17
levels. Both EFNB2 and SEMA3G serve as guidance molecules in
endothelial cells. EFNB2 and its counter-receptor EPHB4 are
expressed on developing arteries and veins respectively, and
repulsive signaling between the two molecules has been suggested
to maintain the boundaries between the two types of vessels during
network formation [42]. The identification of EFNB2 as a SOX18
target fits well to the recent observations that SOX18 knock-down
in the zebrafish results in impaired arteriovenous specification
[15,16]. Less information exists for SEMA3G, a member of larger
family of phylogenetically conserved secreted and membrane-
bound proteins. SEMA3G is a secreted molecule that binds to
Neuropilin-2, but not Neuropilin-1, receptors that are also bound
by certain VEGF forms. In neuronal development, SEMA3G
induced the repulsion of sympathetic, but not dorsal root ganglion
axons, indicating that it can selectivity repel specific types of axons
[43]. Semaphorin class 3 family members have been suggested as
modulators of angiogenesis [44]. Together, and also considering
the additional upregulation of EPHA7 (which, however, did not
clearly respond to SOX18 knock-down), suggests that one function
of SOX18 may be the control of directed vessel formation. For
reasons unknown, we did not identify VCAM-1, a published
Sox18 target gene; one explanation could be that our experimental
setup of Sox18 overexpression as a primary screen would allow
solely the identification of genes for which Sox18 is alone
sufficient, but not those where it is necessary (in combination
with other factors). We also did not find Prox1 in HUVEC,
however Sox18 could induce its expression in endothelial
progenitor cells (not shown). This is consistent with the finding
that Coup-TFII has been identified as a cofactor for Prox1 initial
expression and maintainance [22].
Since a single transcription factor usually participates in the
regulation of several genes, mutations that impair its function can
be expected to affect a broad spectrum of genes and result in a
complex phenotype. Diminished MMP7 expression as a result of a
mutated SOX18 may already affect several aspects of angiogen-
esis, both in the developing as well as the adult organism. In
addition, the identification of EFNB2 and SEMA3G suggests a
role for SOX18 in vessel guidance.
Taken together, the present work represents a functional way to
identify potential SOX18 target genes. With the identification of
MMP7 and performed functional analysis, the direct regulatory
relationship between SOX18 and MMP7 was demonstrated.
Future studies will focus on other potential target genes identified
by this approach, to further investigate the role of SOX18 and its
target genes in vessel formation. With the more detailed
characterization of additional direct Sox18 target genes a better
understanding of the molecular mechanisms of SOX18 in the
ragged phenotype in mice and the HLT syndrome in humans will
be gained.
Supporting Information
Figure S1 Overexpression of Sox18 by a recombinant
adenovirus. HUVEC were either mock transfected or trans-
fected with a recombinant adenovirus for expression of GFP or of
Sox18 as indicated, and mRNA isolated 16 hours later and
analyzed by real-time PCR for expression of Sox7, -17 and -18.
Values were normalized to ß2-microglobulin.
(TIF)
Figure S2 Crossreactivity of Sox18 antibody. A, HEK293
cells were transfected with myc-tagged expression vectors for Sox7,
-17, and -18, or empty vector (EV), and protein extracts analyzed
by Western blotting using anti-myc and anti-Sox18 (SantaCruz).
B, repetition of the experiment using Sox17 and -18 and different
times of exposure.
(TIF)
Table S1 Primers used for constructs, real-time PCR, EMSA,
ChIP, and knock-down experiments.
(DOC)
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